Skip to content

BioSig Technologies, Inc. STEX Sale of investments

Sale of investments at other companies

TEC
Bio-TechneTECH
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-61.8%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%
Debt / equity
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s sale of investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s sale of investments?
BioSig Technologies, Inc. (STEX) reported sale of investments of $10.19M in Q1 2026.
What does sale of investments mean?
This represents cash inflows from the sale of marketable securities, such as corporate bonds or government debt, classified as available-for-sale. It reflects the company's active management of its liquid investment portfolio.